MUSCLE & BACK PAIN RELIEF WITH IBUPROFEN TABLET

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

METHOCARBAMOL; IBUPROFEN

זמין מ:

TEVA CANADA LIMITED

קוד ATC:

M03BA53

INN (שם בינלאומי):

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

כמות:

500MG; 200MG

טופס פרצבטיות:

TABLET

הרכב:

METHOCARBAMOL 500MG; IBUPROFEN 200MG

מסלול נתינה (של תרופות):

ORAL

יחידות באריזה:

18/40

סוג מרשם:

OTC

איזור תרפויטי:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

leaflet_short:

Active ingredient group (AIG) number: 0248961001; AHFS:

מצב אישור:

CANCELLED POST MARKET

תאריך אישור:

2021-08-12

מאפייני מוצר

1 | P a g e
PRODUCT MONOGRAPH
MUSCLE & BACK PAIN RELIEF WITH IBUPROFEN
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED.
Date of Preparation:
30 Novopharm Court,
May 1, 2013
Toronto, Ontario
Canada, M1B 2K9
Control# 164010
2 | P a g e
TABLE OF CONTENTS
Clinical Pharmacology
..............................................................................................................................
3
Indications:
................................................................................................................................................
7
Contraindications
......................................................................................................................................
8
Warnings:
..................................................................................................................................................
8
Precautions
..............................................................................................................................................
12
Drug Interactions
....................................................................................................................................
13
Adverse Reactions
..................................................................................................................................
15
Symptoms and Treatment of Overdose
...................................................................................................
17
Dosage and
Administration.....................................................................................................................
18
Pharmaceutical Information
....................................................................................................................
19
Composition:
...........................................................................................................................................
21
Availability of Dosage Forms
..............